Detail of "637-07-0"

Reference

Effect of hypolipidemic drugs on the metabolism of lauric acid and dimethylaminoazobenzene by rat liver microsomes

Effect of hypolipidemic drugs on the metabolism of lauric acid and dimethylaminoazobenzene by rat liver microsomes.Some chemicals with cas registry numbers like 3307-39-9 and 143-07-7 are also used. Raza, Haider; Levine, Walter G. (Dep. Mol. Pharmacol., Albert Einstein Coll. Med., Bronx, NY 10461, USA). Biochem. Pharmacol., 36(5), 774-8 (English) 1987. CODEN: BCPCA6. ISSN: 0006-2952. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Studies of the effect of 13 hypolipidemics [including clofibrate (I) [637-07-0] and nafenopin (II) [3771-19-5]] and structurally related compds. upon hydroxylation of lauric acid [143-07-7] and upon azo-redn., N-demethylation, and ring hydroxylation of dimethylaminoazobenzene [29387-92-6] by rat liver microsomes revealed no clear structure-activity relations nor relations between the hypolipidemic activity of drugs and their effects on laurate and dimethylaminoazobenzine metab. It appears that different forms of cytochrome P 450 are responsible for laurate hydroxylation and azo-redn. of dimethylaminoazobenzine. .

Concomitant induction of cytosolic but not microsomal epoxide hydrolase with peroxisomal b-oxidation by various hypolipidemic compounds

Concomitant induction of cytosolic but not microsomal epoxide hydrolase with peroxisomal b-oxidation by various hypolipidemic compounds. Schladt, Ludwig; Hartmann, Renate; Timms, Christopher; Strolin-Benedetti, M.; Dostert, P.Several substances are used for example 50-78-2 and 4238-71-5 which are their cas registry numbers.; Woerner, Walter; Oesch, Franz (Inst. Toxikol., Univ. Mainz, Mainz D-6500, Fed. Rep. Ger.). Biochem. Pharmacol., 36(3), 345-51 (English) 1987. CODEN: BCPCA6. ISSN: 0006-2952. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The effects of two cholesterol-lowering (probucol [23288-49-5] and 1-benzylimidazole [4238-71-5]), three triglyceride- and cholesterol-lowering (clofibrate [637-07-0], tiadenol [6964-20-1] and fenofibrate [49562-28-9]) and one triglyceride-lowering acetylsalicylic acid [50-78-2]) compds. on the specific activities of two lipid-metabolizing enzymes (cyanide-insensitive peroxisomal b-oxidn. system and palmitoyl-CoA hydrolase [9025-87-0]) and two xenobiotic metabolizing enzymes [cytosolic (cEH) and microsomal (mEHb) epoxide hydrolase [9048-63-9]] from the livers of rats were investigated. With the exception of probucol and acetylsalicylic acid, all compds. tested caused a dose-dependent hepatomegaly. Taken on a wt. basis fenofibrate was the most effective inducer, causing a 20-fold induction of peroxisomal b-oxidn., a 13-fold induction of cEH activity and a 16-fold induction of palmitoyl-CoA hydrolase activity. The other compds. with triglyceride-lowering activity also induced cEH as well as peroxisomal b-oxidn. and palmitoyl-CoA hydrolase activity. The potency of each individual drug was similar for induction of cEH activity as compared with that of peroxisomal b-oxidn. and palmitoyl-CoA hydrolase activity, but very dissimilar for mEHb, which upon treatment with any of the triglyceride-lowering compds. was either not or only minimally (<1.5-fold) induced. 1-Benzylimidazole possessing exclusively cholesterol-lowering activity increased mEHb much more than either cEH or peroxisomal b-oxidn. The absence of an enhancement of cEH activity in in vitro studies confirmed that the increase in enzyme activity by the test compds. is not caused by activation. CEH activity was also induced in the kidney but only about 2-fold by fenofibrate, tiadenol and acetylsalicylic acid. With hypolipidemic drugs varying in their peroxisome-proliferating potency from inactive to very potent, the effects on peroxisomal b-oxidn. and cEH were similar in all instances, whilst the effects on mEHb could be clearly dissocd. Thus, in the rat a concomitant regulation of cEH with peroxisomal b-oxidn. and peroxisome proliferation by hypolipidemic drugs becomes apparent. .